ClinicalTrials.gg

Pancreatitis clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 558 studies for Pancreatitis across more than 10 countries. 165 are recruiting or about to start. 406 of them are mainly about Pancreatitis (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-16. Counting its 3 narrower conditions too, such as Pancreatitis, Chronic: 836 studies, 230 open.

ClinicalTrials.gov finds 920 studies for Pancreatitis. How that becomes 557 here

This page counts the studies the registry files under Pancreatitis, and those it files under no condition that list Pancreatitisthemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 8, 2026. How condition pages count

  1. 920Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
  2. −276Filed under a narrower condition, counted on its own pagePancreatitis, Chronic 212 · Pancreatitis, Acute Necrotizing 43 · Autoimmune Pancreatitis 18
  3. −28List Pancreatitis as a condition, but the registry did not file them under itMost often written as “Hereditary Pancreatitis” (6), “Biliary Pancreatitis” (3), and “Post-ERCP Acute Pancreatitis” (3). The registry filed them under other conditions only, most often Cholecystitis (7) and Hereditary pancreatitis (6).
  4. −59Match it another way51 name it in the title and 8 in a keyword.
  5. 557The count on this page68 of them list Pancreatitis in their own words; the registry filed them under no condition.

Status

Completed
231
Recruiting
112
Status unknown
97
Not yet recruiting
46
Terminated
35
Active, not recruiting
13

Phase

Phase 2
64
Phase 4
56
Phase 3
40
Phase 1
27
Early Phase 1
7

Where

United States
139
China
104
Spain
21
Germany
21
Italy
20
India
18

Who develops what

Add Pancreatitis to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 5 programs from 4 companies, 1 with this as their studies’ main aim; 1 with a live phase 3 study; 2 primary completions in the next 12 months. Compare Jiangsu HengRui Medicine and Huadong Medicine here →

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

None given by two companies or more yet.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

The 5 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (2)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • Jun 2027 est.HRS-7249, SHR-1918 · Jiangsu HengRui Medicine Co., Ltd. · Phase 2 named, not the main aimNCT07308392 Phase II Clinical Trial Evaluating the Efficacy and Safety of HRS-7249 and SHR-1918 in Patients With Severe Hypertriglyceridemia at High Risk of Acute Pancreatitis — primary endpoint: Percentage change in mean TG from baseline at weeks 44 and 48 of treatment · 119 enrolled
  • Nov 2027 est.SGC001 · Beijing Sungen Biomedical Technology Co., Ltd · Phase 2 main aimNCT07803965 Study of SGC001 Injection for Predicted Severe Acute Pancreatitis to Assess Safety, Tolerability and Preliminary Efficacy — primary endpoint: Part A: Safety Adverse Event (AE) · 129 enrolled

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Pancreatitis studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here NSAIDs 6 open · Corticosteroids 2 open · Antimetabolites 3

Coming up

59studies finish main data collection within a year4 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 112 Pancreatitis studies recruiting now, 62 (55%) set no upper age limit and 27 (24%) stop at 75 or younger. 14 (13%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 12 (11%) take healthy volunteers.

Recruiting studies that take each age, of 112
AgeWomenMen
1012 (11%)12 (11%)
18109 (97%)109 (97%)
30108 (96%)108 (96%)
40108 (96%)108 (96%)
50108 (96%)108 (96%)
65106 (95%)106 (95%)
7597 (87%)97 (87%)
8578 (70%)78 (70%)

Across all 558 studies, recruiting or not: 22% stop at 75 or younger and 9% at 65; 14% take children; 0% are for women only and 0% for men only; 10% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Pancreatitis studies take

Of 22 phase 2 interventional studies under Pancreatitis, half reached primary completion within 31 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 231 mo16–110 · 22 studies——
Interventional, no phase32 mo23–59 · 94 studies—32 mo23–59 · 91 studies
Observational50 mo21–133 · 86 studies—50 mo23–133 · 82 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 18, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 558. Browse all 558 → or search them.